Literature DB >> 20180638

Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.

Joakim E Swedberg1, Simon J de Veer, Jonathan M Harris.   

Abstract

The kallikreins and kallikrein-related peptidases are serine proteases that control a plethora of developmental and homeostatic phenomena, ranging from semen liquefaction to skin desquamation and blood pressure. The diversity of roles played by kallikreins has stimulated considerable interest in these enzymes from the perspective of diagnostics and drug design. Kallikreins already have well-established credentials as targets for therapeutic intervention and there is increasing appreciation of their potential both as biomarkers and as targets for inhibitor design. Here, we explore the current status of naturally occurring kallikrein protease-inhibitor complexes and illustrate how this knowledge can interface with strategies for rational re-engineering of bioscaffolds and design of small-molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180638     DOI: 10.1515/BC.2010.037

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  8 in total

Review 1.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

2.  A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Authors:  Amiram Sananes; Itay Cohen; Anat Shahar; Alexandra Hockla; Elena De Vita; Aubry K Miller; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2018-06-22       Impact factor: 5.157

3.  Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network.

Authors:  Joakim E Swedberg; Simon J de Veer; Kei C Sit; Cyril F Reboul; Ashley M Buckle; Jonathan M Harris
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

Review 4.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

5.  A Versatile and Robust Serine Protease Inhibitor Scaffold from Actinia tenebrosa.

Authors:  Xingchen Chen; Darren Leahy; Jessica Van Haeften; Perry Hartfield; Peter J Prentis; Chloé A van der Burg; Joachim M Surm; Ana Pavasovic; Bruno Madio; Brett R Hamilton; Glenn F King; Eivind A B Undheim; Maria Brattsand; Jonathan M Harris
Journal:  Mar Drugs       Date:  2019-12-12       Impact factor: 5.118

6.  KLK-targeted Therapies for Prostate Cancer.

Authors:  Koistinen Hannu; Mattsson Johanna; Stenman Ulf-Håkan
Journal:  EJIFCC       Date:  2014-09-04

7.  Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency.

Authors:  Xavier Charest-Morin; Jacques Hébert; Georges-Étienne Rivard; Arnaud Bonnefoy; Eric Wagner; François Marceau
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

8.  Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif.

Authors:  Xingchen Chen; Blake T Riley; Simon J de Veer; David E Hoke; Jessica Van Haeften; Darren Leahy; Joakim E Swedberg; Maria Brattsand; Perry J Hartfield; Ashley M Buckle; Jonathan M Harris
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.